Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001
- Written by PR Newswire
![]() |
SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout
PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced full enrollment of a Phase 2b study for its...
Read more: Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001















